Edgewise Therapeutics (EWTX) Non Operating Income (2024 - 2025)
Edgewise Therapeutics (EWTX) posted Non Operating Income of $6.2 million for Q3 2025, down 4.67% sequentially from $6.5 million in Q2 2025, and down 1.76% YoY from $6.3 million in Q3 2024.
Edgewise Therapeutics (EWTX) Non Operating Income (2024 - 2025) Analysis & Trends
Edgewise Therapeutics has reported Non Operating Income for 2 years, with the latest figure at $6.2 million in Q3 2025.
- Quarterly Non Operating Income fell 1.76% year-over-year to $6.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $23.7 million (changed N/A YoY) and the FY2024 annual result came in at $25.0 million, up 76.26% from the prior year.
- Non Operating Income fell to $6.2 million in Q3 2025 per EWTX's latest filing, from $6.5 million in the prior quarter.
- Over five years, Non Operating Income peaked at $6.6 million in Q2 2024 and troughed at $5.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 6.19 Mn |
| Jun 30, 2025 | 6.50 Mn |
| Mar 31, 2025 | 5.16 Mn |
| Dec 31, 2024 | 5.88 Mn |
| Sep 30, 2024 | 6.30 Mn |
| Jun 30, 2024 | 6.61 Mn |
| Mar 31, 2024 | 6.23 Mn |